Pembrolizumab-Induced High Inflammatory Panmyelitis: Contribution of Neurochemical Markers Predicting Severity of Central Nervous Affection.
1/5 보강
This is the first documented case of recurrent, severe, and highly inflammatory panmyelitis induced by pembrolizumab.
APA
Hagenkötter B, De Sèze J, et al. (2025). Pembrolizumab-Induced High Inflammatory Panmyelitis: Contribution of Neurochemical Markers Predicting Severity of Central Nervous Affection.. Oncology and therapy, 13(4), 1255-1260. https://doi.org/10.1007/s40487-025-00374-y
MLA
Hagenkötter B, et al.. "Pembrolizumab-Induced High Inflammatory Panmyelitis: Contribution of Neurochemical Markers Predicting Severity of Central Nervous Affection.." Oncology and therapy, vol. 13, no. 4, 2025, pp. 1255-1260.
PMID
40911258 ↗
Abstract 한글 요약
This is the first documented case of recurrent, severe, and highly inflammatory panmyelitis induced by pembrolizumab. A 41-year-old woman with nodular melanoma developed tetraparesis after three cycles of pembrolizumab treatment. Spinal magnetic resonance imaging (MRI) revealed extensive longitudinal panmyelitis, and cerebrospinal fluid analysis showed markedly elevated cell counts (3900/mm). Follow-up measurements of neurofilament light chain (NfL) levels correlated with the severity of central nervous system involvement and reflected clinical, radiological, and biochemical progression. The clinical outcome was surprisingly favorable following treatment with intravenous immunoglobulins (IVIG) and corticosteroids.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.
- The Role of Vitamins and Micronutrients in the Prevention of Melanoma: A Review of Current Evidence.
- Clinical, Dermatoscopic, Histological and Molecular Prognostic and Predictive Factors of Metastatic Melanoma Response to Immunotherapy: A Systematic Review and Drug Class Meta-Analysis.
- Unraveling the Enigma of Melanoma Brain Metastasis: New Molecular Insights and Therapeutic Directions.
- Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
- Tumor immune-vascular crosstalk: synergy and translation of immune checkpoint inhibitors and anti-angiogenic agents in melanoma.